Provocative testing using low dose oral flecainide for diagnosis of Brugada syndrome: a report of two cases.
Muzakkir AmirPeter KaboIznaeny RahmaPublished in: European heart journal. Case reports (2022)
A potent sodium channel blocker facilitates marked reduction of the right ventricle epicardial action potential, which creates a transmural voltage dispersion and manifests as an ST elevation in the right precordial leads. Time to positivity was comparably rapid, and time to maximal ST-elevation appeared close to peak plasma level of Flecainide (ranging from 1 to 6 h). Although asymptomatic patients have a low rate of adverse cardiac events, it is crucial to inform patients to avoid various modulators and precipitating factors that could trigger malignant arrhythmias.
Keyphrases
- end stage renal disease
- low dose
- chronic kidney disease
- ejection fraction
- peritoneal dialysis
- prognostic factors
- small molecule
- left ventricular
- blood pressure
- pulmonary artery
- coronary artery
- pulmonary hypertension
- mitral valve
- patient reported outcomes
- climate change
- heart rate
- pulmonary arterial hypertension
- body composition
- angiotensin converting enzyme
- sensitive detection